doi: Shetty, R., Basheer, F.T., Pooja Gopal Poojari, Girish Thunga, Chandran, V.P
Current Evidence The straightforward answer is that whilst preliminary research is encouraging, there is currently no official link established between GLP-1 receptor agonist use and dementia prevention or treatment
Technical Remarks When CGM is used in individuals with pre-existing diabetes, providers and patients should use fasting and postprandial glucose targets (whether measured by CGM or SMBG) as the basis for insulin adjustment and not a single glucose target of 63140 mg/dL When using CGM in conjunction with HCL, providers should be aware that not all HCL algorithms can meet these targets This recommendation applies to all types of pre-existing diabetes, including type 1 diabetes and type 2 diabetes There are limited data on the appropriate lower limit of the target for fasting or postprandial glucose in pregnancy
The relationship between GLP-1 therapy and electrolyte balance centres on several key factors: Firstly, the gastrointestinal side effects commonly experienced with GLP-1 medications can lead to significant fluid and electrolyte losses
Dyslipidemia affected approximately 40%